-+ 0.00%
-+ 0.00%
-+ 0.00%

MiNK Therapeutics Q2 EPS $(0.62) Misses $(0.60) Estimate

Benzinga·08/13/2026 11:32:31
Listen to the news
MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.60) by 3.33 percent. This is a 41.51 percent increase over losses of $(1.06) per share from the same period last year.